ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE
Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...
Oncoclínicas&Co has revenues of R$6 billion and profit of R$313 million in 2023
Increase in the number of patients treated and gains in operational efficiency explain record results SÃO PAULO, April 2, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3) – the largest group dedicated to cancer treatment inLatin America – reported a 35.1% growth in its gross revenue in 2023, tot...
Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million
Efficient management of working capital explains a large part of the cash flow performance. Net income grew 51% (31% organically) while the Ebitda Ex-LTIP (excluding only the non-cash impact of the long-term incentive plan) reached R$268 million, 109% greater than the same period last year SÃO PA...
Oncoclínicas Group records a net revenue of BRL 41 million for Q123
The company reported 171 million for the last twelve months, with a 60% growth in net revenue and its best EBITDA ever SAO PAULO, May 22, 2023 /PRNewswire/ -- Oncoclínicas Group (ONCO3) - the largest group dedicated to cancer treatment inLatin America - announced its results for the first quarte...
